HRP20030695B1 - Process for the preparation of imidazole compounds - Google Patents

Process for the preparation of imidazole compounds

Info

Publication number
HRP20030695B1
HRP20030695B1 HR20030695A HRP20030695A HRP20030695B1 HR P20030695 B1 HRP20030695 B1 HR P20030695B1 HR 20030695 A HR20030695 A HR 20030695A HR P20030695 A HRP20030695 A HR P20030695A HR P20030695 B1 HRP20030695 B1 HR P20030695B1
Authority
HR
Croatia
Prior art keywords
preparation
methyl
chlorophenyl
imidazole compounds
quinolinone
Prior art date
Application number
HR20030695A
Other languages
English (en)
Croatian (hr)
Inventor
Ferdinand Maria Filliers Walter
Laurent Maria Broeckx Rudy
Marcel Herman Leurs Stefan
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of HRP20030695A2 publication Critical patent/HRP20030695A2/hr
Publication of HRP20030695B1 publication Critical patent/HRP20030695B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Resins (AREA)
HR20030695A 2001-03-12 2003-09-01 Process for the preparation of imidazole compounds HRP20030695B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01200928 2001-03-12
PCT/EP2002/002459 WO2002072574A1 (en) 2001-03-12 2002-03-05 Process for the preparation of imidazole compounds

Publications (2)

Publication Number Publication Date
HRP20030695A2 HRP20030695A2 (en) 2005-02-28
HRP20030695B1 true HRP20030695B1 (en) 2011-07-31

Family

ID=8180004

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030695A HRP20030695B1 (en) 2001-03-12 2003-09-01 Process for the preparation of imidazole compounds

Country Status (32)

Country Link
US (1) US6844439B2 (no)
EP (1) EP1373255B1 (no)
JP (1) JP4257698B2 (no)
KR (1) KR100849042B1 (no)
CN (1) CN1246318C (no)
AR (1) AR035944A1 (no)
AT (1) ATE287882T1 (no)
AU (1) AU2002253101B2 (no)
BR (1) BRPI0208075B8 (no)
CA (1) CA2438421C (no)
CZ (1) CZ300622B6 (no)
DE (1) DE60202755T2 (no)
DK (1) DK1373255T3 (no)
EA (1) EA006770B1 (no)
EE (1) EE05247B1 (no)
ES (1) ES2236505T3 (no)
HK (1) HK1063315A1 (no)
HR (1) HRP20030695B1 (no)
HU (1) HU230282B1 (no)
IL (2) IL157839A0 (no)
MX (1) MXPA03008205A (no)
MY (1) MY124838A (no)
NO (1) NO324954B1 (no)
NZ (1) NZ528620A (no)
PL (1) PL208238B1 (no)
PT (1) PT1373255E (no)
SI (1) SI1373255T1 (no)
SK (1) SK287807B6 (no)
TW (1) TWI249532B (no)
UA (1) UA74871C2 (no)
WO (1) WO2002072574A1 (no)
ZA (1) ZA200307117B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2291455T3 (es) 2001-03-12 2008-03-01 Avanir Pharmaceuticals Compuestos de bencimidazol para modular ige e inhibir la proliferacion celular.
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
AU2003270426A1 (en) 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
JP2007538004A (ja) * 2004-03-18 2007-12-27 ザ ブライハム アンド ウイメンズ ホスピタル, インコーポレイテッド シヌクレイノパチーを治療する方法
US7524961B2 (en) 2004-05-03 2009-04-28 Janssen Pharmaceutica, N.V. Diastereoselective addition of lithiated N-methylimidazole on sulfinimines
JP4917022B2 (ja) * 2004-05-03 2012-04-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 6−ブロモ−4−(3−クロロフェニル)−2−メトキシ−キノリンを用いるジアステレオ選択的合成方法
ATE397600T1 (de) 2004-05-03 2008-06-15 Janssen Pharmaceutica Nv Diastereoselektives syntheseverfahren zur herstellung vn imidazolverbindungen
EP1968591A4 (en) 2005-12-23 2010-02-17 Link Medicine Corp TREATMENT OF SYNUCLEINOPATHIES
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
KR101044430B1 (ko) * 2009-09-25 2011-06-27 듀오백코리아 주식회사 요추받이를 포함하는 의자의 등 지지 장치
KR101107900B1 (ko) * 2009-10-21 2012-01-25 성용기업 주식회사 의자용 허리지지장치
PT3277842T (pt) 2015-08-17 2019-09-05 Kura Oncology Inc Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase
EP3838275A1 (en) 2016-11-03 2021-06-23 Kura Oncology, Inc. Farnesyltransferase inhibitors for use in methods of treating cancer
US10954210B2 (en) 2016-12-08 2021-03-23 Hangzhou Solipharma Co., Ltd. Crystal form of tipifarnib and preparation method and pharmaceutical composition thereof
AU2019270163A1 (en) * 2018-05-18 2020-12-03 Kura Oncology, Inc. Synthesis of tipifarnib

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021701A1 (en) * 1995-12-08 1997-06-19 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
WO2000012499A1 (en) * 1998-08-27 2000-03-09 Pfizer Products Inc. Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW349948B (en) 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
TW591030B (en) 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
CA2288140C (en) 1997-04-25 2007-04-03 Janssen Pharmaceutica N.V. Farnesyltransferase inhibiting quinazolinones
ES2237125T3 (es) 1998-08-27 2005-07-16 Pfizer Products Inc. Derivados de quinolin-2-ona utiles como agentes anticancerigenos.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021701A1 (en) * 1995-12-08 1997-06-19 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
WO2000012499A1 (en) * 1998-08-27 2000-03-09 Pfizer Products Inc. Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents

Also Published As

Publication number Publication date
CN1496363A (zh) 2004-05-12
CZ300622B6 (cs) 2009-07-01
NO20034003L (no) 2003-10-22
WO2002072574A1 (en) 2002-09-19
EA200300998A1 (ru) 2004-02-26
MY124838A (en) 2006-07-31
US20040138256A1 (en) 2004-07-15
SK12462003A3 (sk) 2004-06-08
MXPA03008205A (es) 2004-01-29
BRPI0208075B8 (pt) 2021-05-25
KR20030079971A (ko) 2003-10-10
HK1063315A1 (en) 2004-12-24
ZA200307117B (en) 2004-09-13
CA2438421A1 (en) 2002-09-19
PT1373255E (pt) 2005-05-31
NO20034003D0 (no) 2003-09-10
HRP20030695A2 (en) 2005-02-28
SI1373255T1 (no) 2005-08-31
SK287807B6 (sk) 2011-10-04
HUP0303443A3 (en) 2012-09-28
TWI249532B (en) 2006-02-21
NO324954B1 (no) 2008-01-14
CZ20032704A3 (en) 2004-03-17
AR035944A1 (es) 2004-07-28
HUP0303443A2 (hu) 2004-01-28
AU2002253101B2 (en) 2007-08-09
CA2438421C (en) 2010-05-18
IL157839A (en) 2008-07-08
PL363263A1 (en) 2004-11-15
IL157839A0 (en) 2004-03-28
EE200300442A (et) 2003-12-15
EP1373255A1 (en) 2004-01-02
JP2004523575A (ja) 2004-08-05
DE60202755D1 (de) 2005-03-03
EP1373255B1 (en) 2005-01-26
BR0208075A (pt) 2004-03-02
CN1246318C (zh) 2006-03-22
PL208238B1 (pl) 2011-04-29
DK1373255T3 (da) 2005-05-23
EE05247B1 (et) 2009-12-15
KR100849042B1 (ko) 2008-07-29
ES2236505T3 (es) 2005-07-16
ATE287882T1 (de) 2005-02-15
BRPI0208075B1 (pt) 2018-02-14
US6844439B2 (en) 2005-01-18
DE60202755T2 (de) 2006-03-30
JP4257698B2 (ja) 2009-04-22
NZ528620A (en) 2005-01-28
UA74871C2 (en) 2006-02-15
EA006770B1 (ru) 2006-04-28
HU230282B1 (hu) 2015-12-28

Similar Documents

Publication Publication Date Title
HRP20030695B1 (en) Process for the preparation of imidazole compounds
CA2422379A1 (en) Pyrazole compounds useful as protein kinase inhibitors
MA30952B1 (fr) Cyclopenta [d] pyrimidines utiles en tant qu'inhibiteurs de la proteine kinase akt
HRP20080226T3 (en) Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
MA29799B1 (fr) Administration d'inhibiteurs de dipeptidyl peptidase
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
WO1997020823A3 (en) 2-amino quinazoline derivatives as npy receptor antagonists
HUP0201659A2 (hu) Kristályos benzimidazol-vegyület
BRPI0416143A (pt) sais farmaceuticamente aceitáveis de compostos de quinolinona tendo propriedades farmacêuticas aperfeiçoadas
TR200102839T2 (tr) LH agonistleri olarak faydalı bisiklik heteroaromatik bileşikler.
ATE355278T1 (de) Isochinolinon derivate als parp inhibitoren
BG106969A (en) Cristalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulphonyl) amino]pyrimidine-5-yl]-(3r, 5s)- 3,5-dihydroxyhept-6-enoic acid
DK1070056T3 (da) Phthalazinon-PDE III/IV-inhibitorer
AP2004003059A0 (en) Salt forms of E-2-methoxy-N-(3-(4-(3-methyl-pyridin-3-yloxyl)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
WO2001064645A3 (en) Derivatives of quinoline as alpha-2 antagonists
CA2412208A1 (en) Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators
DK0900214T3 (da) Fremgangsmåde til fremstilling af pyrmidin-derivater
RU2002118304A (ru) Способ подавления чувства страха
WO2003051838A3 (en) Protein kinase inhibitors
HK1101580A1 (en) Diastereoselective synthesis process for the preapration of imidazole compounds
HUP0300006A3 (en) 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylat and polymorphs, process for their preparation and pharmaceutical compositions containing them
WO2002062798A3 (en) Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose
WO2002018363A3 (en) 3-phenyl-propanoic acid derivatives as protein tyrosine phosphatase inhibitors
NO20034690L (no) Fremgangsmåte for behandling av tumorer ved administrering av tegafur, uracil, folinsyre og cyklofosfamid
NZ516201A (en) Quinolinecarboxylic acid derivative or salts thereof that have antimicrobial effect

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20190218

Year of fee payment: 18

ODRP Renewal fee for the maintenance of a patent

Payment date: 20200210

Year of fee payment: 19

ODRP Renewal fee for the maintenance of a patent

Payment date: 20210211

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20220305